Our group successfully inhibited the growth of multiple myeloma and CRC cells using OTS514, a specific PBK inhibitor (Figures 2C,D) (Ota et al., 2020; Nagano-Matsuo et al., 2021). Here, PBK is linked to plasma cell myeloma.